<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196325</url>
  </required_header>
  <id_info>
    <org_study_id>09-0258-BE</org_study_id>
    <nct_id>NCT01196325</nct_id>
  </id_info>
  <brief_title>Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy</brief_title>
  <acronym>VEGF</acronym>
  <official_title>Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate changes in the structure and function of blood vessels in the&#xD;
      front and back of the eye following laser and anti-VEGF treatments for sight-threatening&#xD;
      diabetic eye disease. Sixty four volunteers will be recruited, including age-matched control&#xD;
      subjects and diabetic patients who require conventional or contemporary treatment for&#xD;
      pre-existing diabetic eye disease. Volunteers will be assessed before and after treatment&#xD;
      using state-of-the-art techniques to measure vision, the rate of blood flow and structure at&#xD;
      the front and back of the eye and the effectiveness of blood flow delivery. Changes following&#xD;
      treatment in these novel, non-invasive techniques will be quantified and described. We&#xD;
      anticipate that conventional and new / developing treatments will lead to narrowing of the&#xD;
      vessels and consequent reduction of blood flow at the back and front of the eye. There will&#xD;
      be a strong relationship between structural changes of the eye and functional changes of&#xD;
      blood vessels at the front and back of the eye. The results of this study will improve our&#xD;
      understanding of the impact of the various treatments on the entire eye. The research will&#xD;
      also ensure an improved understanding of the mechanisms of action of the various treatments&#xD;
      and will provide insight of reasons for good or poor outcomes, based upon specific changes in&#xD;
      structure and blood flow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic Retinopathy (DR) is the single leading cause of blindness in people of working age.&#xD;
      The total number of people living with diabetes in Canada is well over 2 million. The WHO&#xD;
      estimates that around 12% of people with diabetes are blind or will develop severe vision&#xD;
      loss. The two most common treatments of DR are: Laser Photocoagulation and anti-VEGF&#xD;
      intravitreal injection. Clinical evidence demonstrates that these treatments lead to&#xD;
      morphological and vascular retinal changes, however the actual mechanism and nature of post&#xD;
      treatment changes is not fully understood. It is only recently that objective and&#xD;
      quantitative imaging and hemodynamic technologies with previously unachievable resolution&#xD;
      have become available that enable us to evaluate and to compare various effects of these&#xD;
      treatments on vital eye structures.&#xD;
&#xD;
      We are proposing to take advantage of these state-of-the-art technologies in order to explore&#xD;
      unknown effects of treatments on vital eye structures. We hypothesize that: 1) Laser&#xD;
      Photocoagulation and anti-VEGF treatments will result in vessel constriction and hence&#xD;
      reduction in posterior (retinal and choroidal) and anterior (conjunctival) ocular blood flow;&#xD;
      2) Changes in anterior segment ocular morphology and blood flow will positively correlate&#xD;
      with changes in posterior segment morphology and blood flow; 3) Combined treatments will&#xD;
      result in a greater reduction in posterior and anterior blood flow than any single treatment;&#xD;
      4) There will be differences in anterior and posterior blood flow outcomes and in anterior&#xD;
      segment oxygen saturation when compared to healthy controls.&#xD;
&#xD;
      The study will include four groups of participants: Laser treatment group; Intravitreal&#xD;
      injection of Bevacizumab treatment group; Intravitreal injection of Ranibizumab treatment&#xD;
      group; Healthy age matched controls. The administration of ranibizumab and bevacizumab will&#xD;
      be randomized across participants. Randomization number will be assigned to each participant&#xD;
      and recorded in a Master Randomization Assignment List. All patients will be recruited from&#xD;
      the Retina Clinics of the Toronto Western Hospital.&#xD;
&#xD;
      Every type 2 diabetic patient with Diabetic Macular Edema will be assessed prior to treatment&#xD;
      and followed-up on the 3rd, 7th,30th day and 3 months after the initial treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative inner retinal blood flow</measure>
    <time_frame>Baseline, 3, 7, 30 days and 3 months</time_frame>
    <description>Inner retinal blood flow will be measured using Canon Laser Blood Flowmeter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean retinal thickness for an annulus centered on fovea</measure>
    <time_frame>Baseline,3,7,30 days, and 3 months</time_frame>
    <description>Mean retinal thickness will be measured using Heidelberg Spectralis Spectral Domain Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (LogMAR, EDTRS)</measure>
    <time_frame>Baseline, 3, 7, 30 days and 3 months</time_frame>
    <description>Best Corrected Visual Acuity will be examined using 96% and 10 % contrast EDTRS letter charts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative anterior blood flow</measure>
    <time_frame>Baseline, 3, 7, 30 days and 3 months</time_frame>
    <description>Quantitative anterior blood flow will be assessed by measuring velocity of individual rbc's (μm/sec) and blood oxygen saturation(%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean angle opening distance and trabecular-iris spur area</measure>
    <time_frame>Baseline, 3, 7, 30 days and 3 months</time_frame>
    <description>Mean angle opening distance and trabecular-iris spur area will be measured by Heidelberg Slit-Lamp Optical Coherence Tomography.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Laser Group</arm_group_label>
    <description>Patients who are clinically indicated for the laser treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-VEGF Group (Bevacizumab)</arm_group_label>
    <description>Patients who are clinically indicated for the intravitreal injection of Bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-VEGF Group (Ranibizumab)</arm_group_label>
    <description>Patients who are clinically indicated for intravitreal injection of Ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age-matched controls</arm_group_label>
    <description>Group of non-diabetic participants who will be age and gender matched</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetic patients with clinically sight-threatening Diabetic Macular Edema will be&#xD;
        recruited from the Retina Clinics of Toronto Western Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range of 35-75 yrs&#xD;
&#xD;
          -  Type 2 diabetes apart from age-matched control group&#xD;
&#xD;
          -  Visual acuity of 20/400 or better&#xD;
&#xD;
          -  Confirmed diagnose of Clinical Significant Diabetic Macular Edema (applies for&#xD;
             Diabetic Groups only)&#xD;
&#xD;
          -  Previously untreated eye for retinal diseases and disorders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distance refractive error &gt; ± 6.00 DS &amp; / or ± 2.50 DC&#xD;
&#xD;
          -  Intraocular pressure ≥ 22mm Hg&#xD;
&#xD;
          -  Proliferative Diabetic Retinopathy&#xD;
&#xD;
          -  Any other active eye disease and disorder&#xD;
&#xD;
          -  Participants with history of cardiovascular events, stroke, thromboembolic events,&#xD;
             transient ischemic attack, uncontrolled hypertension.&#xD;
&#xD;
          -  Any active ocular infection;&#xD;
&#xD;
          -  History of glaucoma;&#xD;
&#xD;
          -  Known allergy, hypersensitivity or contraindication to the study medication;&#xD;
&#xD;
          -  Pregnancy, breast feeding, or women of childbearing potential who are not using a&#xD;
             reliable method of contraception;&#xD;
&#xD;
          -  Proteinuria and/or renal impairment;&#xD;
&#xD;
          -  Surgery within the past 28 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Hudson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olena Puzyeyeva, MD</last_name>
    <phone>(416)603-5694</phone>
    <phone_ext>5694</phone_ext>
    <email>opuzyeye@uhnresearch.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lee-Anne Khuu, MSc</last_name>
    <phone>(416)603-5694</phone>
    <phone_ext>5694</phone_ext>
    <email>lkhuu@uhnresearch.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olena Puzyeyeva, MD</last_name>
      <phone>(416)603-5694</phone>
      <email>opuzyeye@uhnresearch.ca</email>
    </contact>
    <contact_backup>
      <last_name>Lee-Anne Khuu, MSc</last_name>
      <phone>(416)603-5694</phone>
      <email>lkhuu@uhnresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Hudson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Brent, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John G Flanagan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wai-Ching Lam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert G Devenyi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Mandelcorn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Efrem Mandelcorn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Toronto</investigator_affiliation>
    <investigator_full_name>Chris Hudson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>Laser</keyword>
  <keyword>Anti-VEGF</keyword>
  <keyword>Morphology</keyword>
  <keyword>Blood Flow</keyword>
  <keyword>Vision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

